title: Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients.
abstract: Velo-cardio-facial syndrome (VCFS) is a relatively common developmental disorder characterized by craniofacial anomalies and conotruncal heart defects. Many VCFS patients have hemizygous deletions for a part of 22q11, suggesting that haploinsufficiency in this region is responsible for its etiology. Because most cases of VCFS are sporadic, portions of 22q11 may be prone to rearrangement. To understand the molecular basis for chromosomal deletions, we defined the extent of the deletion, by genotyping 151 VCFS patients and performing haplotype analysis on 105, using 15 consecutive polymorphic markers in 22q11. We found that 83% had a deletion and >90% of these had a similar approximately 3 Mb deletion, suggesting that sequences flanking the common breakpoints are susceptible to rearrangement. We found no correlation between the presence or size of the deletion and the phenotype. To further define the chromosomal breakpoints among the VCFS patients, we developed somatic hybrid cell lines from a set of VCFS patients. An 11-kb resolution physical map of a 1,080-kb region that includes deletion breakpoints was constructed, incorporating genes and expressed sequence tags (ESTs) isolated by the hybridization selection method. The ordered markers were used to examine the two separated copies of chromosome 22 in the somatic hybrid cell lines. In some cases, we were able to map the chromosome breakpoints within a single cosmid. A 480-kb critical region for VCFS has been delineated, including the genes for GSCL, CTP, CLTD, HIRA, and TMVCF, as well as a number of novel ordered ESTs.
authors.affiliation: Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
authors.forename: C
authors.initials: C
authors.lastname: Carlson
authors.forename: H
authors.initials: H
authors.lastname: Sirotkin
authors.forename: R
authors.initials: R
authors.lastname: Pandita
authors.forename: R
authors.initials: R
authors.lastname: Goldberg
authors.forename: J
authors.initials: J
authors.lastname: McKie
authors.forename: R
authors.initials: R
authors.lastname: Wadey
authors.forename: S R
authors.initials: SR
authors.lastname: Patanjali
authors.forename: S M
authors.initials: SM
authors.lastname: Weissman
authors.forename: K
authors.initials: K
authors.lastname: Anyane-Yeboa
authors.forename: D
authors.initials: D
authors.lastname: Warburton
authors.forename: P
authors.initials: P
authors.lastname: Scambler
authors.forename: R
authors.initials: R
authors.lastname: Shprintzen
authors.forename: R
authors.initials: R
authors.lastname: Kucherlapati
authors.forename: B E
authors.initials: BE
authors.lastname: Morrow
mesh_terms: D000015:Abnormalities, Multiple / Q000235:genetics; D002869:Chromosome Aberrations / Q000235:genetics*; D002872:Chromosome Deletion; D025063:Chromosome Disorders; D002874:Chromosome Mapping; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics*; D002972:Cleft Palate / Q000235:genetics; D019465:Craniofacial Abnormalities / Q000235:genetics*; D005819:Genetic Markers; D005838:Genotype; D006330:Heart Defects, Congenital / Q000235:genetics*; D006801:Humans; D006822:Hybrid Cells; D010641:Phenotype; D012333:RNA, Messenger / Q000032:analysis; D016324:Sequence Tagged Sites; D013577:Syndrome
chemical_list: D005819:Genetic Markers; D012333:RNA, Messenger